CN103110947A - Additive used for activating platelets - Google Patents
Additive used for activating platelets Download PDFInfo
- Publication number
- CN103110947A CN103110947A CN2011103627887A CN201110362788A CN103110947A CN 103110947 A CN103110947 A CN 103110947A CN 2011103627887 A CN2011103627887 A CN 2011103627887A CN 201110362788 A CN201110362788 A CN 201110362788A CN 103110947 A CN103110947 A CN 103110947A
- Authority
- CN
- China
- Prior art keywords
- additive
- aforementioned
- buffer
- antibiotic
- platelet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an additive used for activating platelets. The additive includes calcium ions, an antibiotic, an antioxidant and a buffer solution. The blood plasma sample additive can be obtained after uniformly mixing required components according to a specific ratio. The additive prepared in the invention has the advantages of simple and rapid use, platelet activation function, and helpfulness for the medical application of the platelets.
Description
Technical field
The present invention is about a kind of additive for blood sample, espespecially a kind of additive for activated blood platelet.
Background technology
Blood clotting is important emergency treatment of human body, and clotting mechanism is divided into exogenous (extrinsic) and endogenous (intrinsic), involves regulation and control and the various thrombin of multilamellar, wherein platelet and calcium ion (Ca
2+) play the part of epochmaking role, platelet regulation and control intrinsic coagulation mechanism, calcium ion then is the cofactor of multiple thrombin, therefore when wound, platelet can produce multiple somatomedin, and then promotes blood coagulation and wound healing.
Platelet rich plasma (Platelet Rich Plasma, PRP) under specific pH value and PC, can produce multiple somatomedin, therefore use it for medically that wound, arthritis, foot that the treatment diabetics is difficult to fully recover fester or burn etc., even also can cooperate skin-grafting to impel the histiocyte Regeneration and Repair, effectiveness is good and side effect is low.
The effect of PRP on using is except having the different lead-in modes according to different treatments, affecting its active the maximum is hematoblastic concentration and its activity among the PRP, the somatomedin that higher concentration or active higher platelet produce is more, the effect for the treatment of is faster also better, though use the how non-emergency case of disease of PRP treatment, if but can improve the effectiveness of each injection PRP, just can reduce blood drawing and the number of times for the treatment of, not only reduce the probability that infects, use manpower and material resources sparingly and alleviate the pain of sufferer, therefore how to make efficiently PRP produce more somatomedin, truly have the necessity of its exploitation.
Summary of the invention
A purpose of the present invention is for providing a kind of method of activated blood platelet, its can promote existing Therapeutic Method effectiveness, help to promote quality of medical care.
Another object of the present invention can activate the platelet in the blood sample for a kind of additive for blood sample is provided, and makes its somatomedin that produces more amount, to obtain better therapeutic effect.
For achieving the above object, the invention provides a kind of additive in order to activated blood platelet, it comprises calcium ion, antioxidant, antibiotic and buffer.
Preferably, the concentration range of aforementioned calcium ion is 0.05 ~ 0.5mEq/ml.
Preferably, the concentration range of aforementioned antioxidant is 100 ~ 400mg/ml; Preferably, aforementioned antioxidant is glutathion, vitamin C, vitamin E, vitamin A, carotenoid, coenzyme, thioctic acid, flavonoid or its combination.
Preferably, aforementioned antibiotic concentration range is 20 ~ 70 μ g/ml; Preferably, aforementioned antibiotic is sulphuric acid gentamycin, streptomycin, lincomycin, penicillin, tetracycline, chloromycetin, erythromycin, sulfonamides or its combination.
Preferably, aforementioned buffer is medical acceptable buffer; Preferably, aforementioned buffer is phosphate buffer solution, Ringer's mixture or its combination.
The present invention provides again a kind of method that activates blood sample, and its step is that sample is mixed with additive.
Preferably, aforementioned incorporation time is 5 ~ 20 minutes.
Preferably, aforementioned sample is blood plasma, and every milliliter contains 100 ~ 300 * 106 platelet.
Preferably, aforementioned sample is for being rich in hematoblastic blood plasma (PRP), and it contains the platelet that concentration surpasses every milliliter 109.
In sum, additive of the present invention more is aided with antioxidant and antibiotic except adding the essential calcium ion of activated blood platelet, increase persistence and safety in the PRP use, therefore helps PRP in application clinically.In addition, additive of the present invention only need simple and blood sample (as, PRP) mix, effect can occur, no matter on the clinical application of detection property, therapeutic or beauty treatment property, all have simple and rapid advantage.
Description of drawings
Fig. 1 is that the embodiment of the invention one is in the result of the test of activated blood platelet.
The specific embodiment
The method of the present invention's activated blood platelet on the clinical application of detection property, therapeutic or beauty treatment property about a kind of additive in order to activated blood platelet and use aforementioned additive.Aforementioned additive comprises calcium ion, antioxidant, antibiotic and the buffer of debita spissitudo.
Alleged " activation " of the present invention means to make to be increased hematoblastic physiologically active and/or promotes its function on physiological mechanism.For instance, as impel platelet to discharge more efficiently somatomedin such as platelet-derived property somatomedin (PDGF-BB), transforming growth factor (TGF-β) and VEGF (VEGF).
" blood sample " general reference mankind that the present invention is alleged or the blood sample of animal; More clearly, mean and be rich in hematoblastic plasma sample.Yet affiliated field has knows the knowledgeable usually, joins the disclosed content of description of the present invention, uses additive of the present invention to make platelet activation contained in any blood sample when understanding, and all should belong to category of the present invention.
The concentration of aforementioned calcium ion is 0.05 ~ 0.5mEq/ml.Aforementioned calcium ion can be provided by calcium ions solution, and it includes, but are not limited to calcium chloride solution, calcium phosphate solution, calcium gluconate or its combination.Because calcium ion is important cofactor (cofactor) in the platelet activation path, therefore, the interpolation calcium ion will help to impel the platelet activation in the blood sample, or the degree of its activation is provided.
The concentration of aforementioned antioxidant is 100 ~ 400mg/ml.Aforementioned antioxidant includes, but are not limited to glutathion, vitamin C, vitamin E, vitamin A, carotenoid, coenzyme, thioctic acid, flavonoid or its combination.In additive of the present invention, add antioxidant and can remove free radical isoreactivity material, prolong the life-span of somatomedin.
Aforementioned antibiotic concentration is 20 ~ 70 μ g/ml.Aforementioned antibiotic includes, but are not limited to sulphuric acid gentamycin, streptomycin, lincomycin, penicillin, tetracycline, chloromycetin, erythromycin, sulfonamides or its combination.In additive of the present invention, add antibiotic and can avoid contingent infection when using plasma sample.
Aforementioned buffer has been to keep the proper pH value environment in additive of the present invention, makes the platelet in the blood sample keep normal physiologically active, and is able to the sustained release somatomedin.Preferably, aforementioned buffer system is controlled in the pH value of additive of the present invention between 5 ~ 8.More clearly, aforementioned buffer is medical acceptable buffer, includes, but are not limited to: Ringer's mixture, phosphate buffer or its combination.
The compound method system of additive of the present invention is summarized as follows: at first, obtain required raw material, comprise calcium ions solution, antioxidant, antibiotic and buffer that wish is used.Aforementioned base materials can directly be chosen commercial pharmaceutical grade reagent through aseptic process, perhaps also can be simple and easy through the laboratory allotment, sterilize according to person with usual knowledge in their respective areas's mode known again.For instance, the mode of sterilization has: filter to reach simultaneously the effect of filtering fine impurities and sterilization through the circular filter membrane (being commonly called as little flying saucer) of 0.22 μ m, perhaps also can make the reagent for preparing in Sterilization Kettle through autoclave sterilization.
It should be noted that, the part medicament also is not suitable for sterilizing in the mode of High Temperature High Pressure, for example, and under such temperature, pressure condition, probably cause antibiotic destruction, therefore affiliated field has knows that usually the knowledgeable is when understanding the mode that need select according to circumstances to adopt sterilization.Preferably, even if employed raw material is the product of just having sterilized at supplier's end, or the operator has sterilized, after additive configuration of the present invention is finished, still can be again through the circular membrane filtration of 0.22 μ m at least one times, to avoid any possibility pollution condition in the process of preparation additive of the present invention.
Obtain after the needed raw material, successively aforementioned calcium ions solution, aforementioned antioxidant and aforementioned antibiotic are added in the aforementioned buffer, the order of its mixing is restriction not, but in order to keep aforementioned antioxidant and aforementioned antibiotic activity, preferably, be to mix first aforementioned calcium ions solution and aforementioned buffer.In addition, also aforementioned calcium ions solution and aforementioned buffer can be mixed into after the mixed liquor, aforementioned mixed liquor is properly preserved, until when needing to use additive of the present invention, the aforementioned mixed liquor that to preserve again takes out, and adds aforementioned antioxidant and aforementioned antibiotic.Can guarantee that thus oxidant and antibiotic activity maintain best situation.
After adding aforementioned calcium ions solution, aforementioned antioxidant and aforementioned antibiotic in the aforementioned buffer, stir or rock all the components can be mixed uniformly.Preferably, in order to keep aforementioned antioxidant and aforementioned antibiotic activity, under room temperature, carry out combination process; More clearly, under 16 ~ 26 ℃, carry out combination process.Finishing after the combination process, as previously mentioned, preferably is again through the circular membrane filtration of at least one times 0.22 μ m, just makes additive of the present invention.
When using additive of the present invention, preferably, aforementioned additive is mixed with blood sample.More clearly, mixed process need continue to rock so that aforementioned additive is mixed fully with plasma sample.Preferably, the time of aforementioned mixing is 5 ~ 20 minutes.
Accordingly, additive of the present invention provides platelet activation required cofactor, and plasma sample is from sufferer itself, does not therefore have the problem of immunologic rejection, is particularly suitable for using somatomedin to promote the medical treatment that tissue is newborn.
Following examples are only with literal and the actual processing procedure that carries out of the graphic explanation of arranging in pairs or groups and experiment, so that the person with usual knowledge in their respective areas more clearly understands characteristics of the present invention and spirit.Only should be noted that following examples only are used for the present invention exemplarily is described, and do not use to limit interest field of the present invention.
Embodiment one: prepare the additive for activated blood platelet of the present invention.
In present embodiment, will exemplarily prepare additive of the present invention.Obtain aseptic buffer, calcium ions solution, antioxidant and antibiotic.In present embodiment, employed buffer is that ringer's solution, employed calcium ions solution are that calcium chloride solution, employed antioxidant are that glutathion and employed antibiotic are the sulphuric acid gentamycin.
At first, the ringer's solution of 1.7 mL is mixed with the calcium chloride solution of 0.5 ml (0.272 mEq/ml), under 20 ℃ condition, add again the glutathion of 250 mg and the sulphuric acid gentamycin (50 μ g/ml) of 4 μ l.Treat that each uniform ingredients mixes and be dissolved to till the no suspended substance, can obtain the additive that is used for activated blood platelet of present embodiment, wherein the calcium ion concentration concentration that is about 0.062 mEq/ml, the glutathion concentration that is about 113.636 mg/ml and sulphuric acid gentamycin is about 45 μ g/ml.
Embodiment two: the using method of the additive of embodiment one and effect analysis.
In present embodiment, after the additive of embodiment one and plasma sample mixed according to actual operating position, the effect of analysis additive.
Aforementioned plasma sample is for being rich in platelet blood plasma (PRP), and its source whole blood for extracting from human body get through the technology purification such as centrifugal, and every milliliter of its PC is above 109.To be rich in platelet blood plasma (PRP) directly mixes under room temperature with embodiment one prepared additive, wherein continue to rock with hands or agitator, so that behind both abundant mixings, it was left standstill 20 minutes, measure again the concentration of wherein platelet-derived property somatomedin (PDGF-BB), transforming growth factor (TGF-β) and VEGF (VEGF).
Please refer to Fig. 1, the concentration of aforementioned three kinds of somatomedin all increases significantly than the somatomedin concentration of whole blood behind its demonstration adding additive.By the data among the figure as can be known, compare with matched group, the additive of embodiment one can promote the about 3.5 times release of platelet-derived property somatomedin, promotes the about 2 times release of transforming growth factor, and promotes the about 3.5 times release of VEGF.
Claims (10)
1. additive in order to activated blood platelet is characterized in that it comprises:
Calcium ion;
Antioxidant;
Antibiotic; And
Buffer.
2. additive as claimed in claim 1, it comprises:
0.05 the calcium ion of ~ 0.5mEq/ml;
The antioxidant of 100 ~ 400mg/ml;
The antibiotic of 20 ~ 70 μ g/ml; And
Buffer.
3. additive as claimed in claim 1, wherein aforementioned buffer is medical acceptable buffer.
4. additive as claimed in claim 1, wherein the pH value scope of aforementioned buffer is 5 ~ 8.
5. additive as claimed in claim 1, wherein aforementioned antioxidant is glutathion, vitamin C, vitamin E, vitamin A, carotenoid, coenzyme, thioctic acid, flavonoid or its combination.
6. additive as claimed in claim 1, wherein aforementioned antibiotic is sulphuric acid gentamycin, streptomycin, lincomycin, penicillin, tetracycline, chloromycetin, erythromycin, sulfonamides or its combination.
7. method of impelling platelet activation, it comprises makes sample and mixes such as Shen additive as claimed in claim 1.
8. method as claimed in claim 7, wherein the time of aforementioned mixing is 5 ~ 20 minutes.
9. method as claimed in claim 7, wherein aforementioned sample is blood plasma.
10. method as claimed in claim 9, wherein aforementioned blood plasma is for being rich in hematoblastic blood plasma (PRP).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103627887A CN103110947A (en) | 2011-11-16 | 2011-11-16 | Additive used for activating platelets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103627887A CN103110947A (en) | 2011-11-16 | 2011-11-16 | Additive used for activating platelets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103110947A true CN103110947A (en) | 2013-05-22 |
Family
ID=48409357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103627887A Pending CN103110947A (en) | 2011-11-16 | 2011-11-16 | Additive used for activating platelets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110947A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697763A (en) * | 2015-12-30 | 2018-10-23 | 通用电气公司 | Activation is controlled by the calcium of the blood platelet of electro photoluminescence |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060085003A1 (en) * | 2004-10-05 | 2006-04-20 | Arthrex, Inc. | Use of autogenous growth factors in bone tunnels during ligament reconstruction |
-
2011
- 2011-11-16 CN CN2011103627887A patent/CN103110947A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060085003A1 (en) * | 2004-10-05 | 2006-04-20 | Arthrex, Inc. | Use of autogenous growth factors in bone tunnels during ligament reconstruction |
Non-Patent Citations (1)
| Title |
|---|
| ELIZAVETA KON ETAL: "Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions", 《KNEE SURG SPORTS TRAUMATOL ARTHROSC》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697763A (en) * | 2015-12-30 | 2018-10-23 | 通用电气公司 | Activation is controlled by the calcium of the blood platelet of electro photoluminescence |
| CN108697763B (en) * | 2015-12-30 | 2022-12-09 | 通用电气公司 | Calcium-controlled activation of platelets by electrical stimulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abegão et al. | Effects of heterologous platelet-rich plasma gel on standardized dermal wound healing in rabbits | |
| CN109276577B (en) | Nitric oxide nano-composite hydrogel and preparation method and application thereof | |
| CN101862469B (en) | Chitosan derivative quick hemostasis granules and preparation method thereof | |
| US10022411B2 (en) | Hemostatic preparation containing an extract of golden moss | |
| CN111803704B (en) | Nursing hemostatic gel and preparation method thereof | |
| You et al. | The effective control of a bleeding injury using a medical adhesive containing batroxobin | |
| CN105816905A (en) | Absorbable bone wax with heal-promoting function and preparation method of absorbable bone wax | |
| CN103083712A (en) | Stem cells or other bioactive substances doped surgical dressing | |
| US20100226902A1 (en) | Method For Treating Wounds With Enriched Platelet Wound Healant | |
| Sinha et al. | Chitosan based Axiostat dental dressing following extraction in cardiac patients under antiplatelet therapy | |
| CN103110947A (en) | Additive used for activating platelets | |
| CN110755674B (en) | Hemostatic powder and preparation method thereof | |
| RU2543344C2 (en) | Method of treating trophic ulcers | |
| CN103495174A (en) | Multi-effect external preparation used for treating superficial skin injury and application thereof | |
| CN107715167A (en) | Chitosan-based hemostatic paste and preparation method as bone wax substitute | |
| CN100379464C (en) | Soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method | |
| Taguchi et al. | Evaluation of tumor tissue fixation effects of formulation modified Mohs pastes in mice and their water-absorbing properties | |
| Caloprisco et al. | Chronic skin ulcers: a regenerative simulation by topical hemotherapy | |
| CN102302770A (en) | Medical composition for accelerating wound healing | |
| TW201317004A (en) | Additive for activating platelet | |
| CN104784167B (en) | A kind of medicine for treating animal eperythrozoonosis and preparation method thereof | |
| Vinay et al. | Platelet rich fibrin dressings in the treatment of non-healing trophic ulcers of leprosy | |
| RU2790831C2 (en) | Method for obtaining hemostatic composition | |
| CN114452435B (en) | High-affinity liquid dressing capable of being rapidly effective | |
| CN102247381A (en) | VitaminD2-and-vitaminE-containing medicinal composition for injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130522 |